Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation

doi:10.1155/2007/89369

Warning: The NCBI web site requires JavaScript to function. more...

My NCBI Sign In

PPAR Res. 2007; 2007: 89369.

Published online 2008 January 17. doi: 10.1155/2007/89369

PMCID: PMC2234255

Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation

Asha Jacob,^{1, 2} Rongqian Wu,^{1, 2} Mian Zhou,^{1, 2} and Ping Wang^{1, 2}^*

Author information ► Article notes ► Copyright and License information ►

This article has been cited by other articles in PMC.

Abstract

Curcumin, the phytochemical component in turmeric, is used as a dietary spice and a topical ointment for the treatment of inflammation in India for centuries. Curcumin (diferuloylmethane) is relatively insoluble in water, but dissolves in acetone, dimethylsulphoxide, and ethanol. Commercial grade curcumin contains 10–20% curcuminoids, desmethoxycurcumin, and bisdesmethoxycurcumin and they are as effective as pure curcumin. Based on a number of clinical studies in carcinogenesis, a daily oral dose of 3.6g curcumin has been efficacious for colorectal cancer and advocates its advancement into Phase II clinical studies. In addition to the anticancer effects, curcumin has been effective against a variety of disease conditions in both in vitro and in vivo preclinical studies. The present review highlights the importance of curcumin as an anti-inflammatory agent and suggests that the beneficial effect of curcumin is mediated by the upregulation of peroxisome proliferator-activated receptor- equation M2 (PPAR- equation M3 ) activation.

Articles from PPAR Research are provided here courtesy of Hindawi Publishing Corporation

Related citations in PubMed

The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. [Crit Care Med. 2006]
The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma.
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P. Crit Care Med. 2006 Jul; 34(7):1874-82.
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ [Gene Ther Mol Biol. 2009]
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ
Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, Moore BB, Leff T, Reddy VD, Kondapi AK, Reddy RC. Gene Ther Mol Biol. 2009 Apr 1; 13(1):20-25.
Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. [J Agric Food Chem. 2005]
Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice.
Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, et al. J Agric Food Chem. 2005 Feb 23; 53(4):959-63.
Pharmacokinetics and pharmacodynamics of curcumin. [Adv Exp Med Biol. 2007]
Pharmacokinetics and pharmacodynamics of curcumin.
Sharma RA, Steward WP, Gescher AJ. Adv Exp Med Biol. 2007; 595:453-70.
Inhibitory effects of curcumin on tumorigenesis in mice. [J Cell Biochem Suppl. 1997]
Inhibitory effects of curcumin on tumorigenesis in mice.
Huang MT, Newmark HL, Frenkel K. J Cell Biochem Suppl. 1997; 27:26-34.

See reviews... See all...

Cited by other articles in PMC

Peroxisome proliferator activated receptor-γ and traumatic brain injury [International Journal of Clinical and Exper...]
Peroxisome proliferator activated receptor-γ and traumatic brain injury
Qi L, Jacob A, Wang P, Wu R. International Journal of Clinical and Experimental Medicine. 3(4)283-292
Neuroprotective and Antiinflammatory Properties of a Novel Demethylated Curcuminoid [Antioxidants & Redox Signaling. 2009]
Neuroprotective and Antiinflammatory Properties of a Novel Demethylated Curcuminoid
Khanna S, Park HA, Sen CK, Golakoti T, Sengupta K, Venkateswarlu S, Roy S. Antioxidants & Redox Signaling. 2009 Mar; 11(3)449-468
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ [Gene therapy & molecular biology. 2009]
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ
Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, Moore BB, Leff T, Reddy VD, Kondapi AK, Reddy RC. Gene therapy & molecular biology. 2009 Apr 1; 13(1)20-25

See all...

Recent activity

Clear Turn Off Turn On

Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation
Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation
PPAR Research. 2007; 200789369

PMC
Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine express...
Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes
Nutrition & Metabolism. 517

PMC
Prevention of hypertension, cardiovascular damage and endothelial dysfunction wi...
Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts.
Am J Hypertens. 2007 Dec ;20(12):1321-8.

PubMed
Characteristics of catechin- and theaflavin-mediated cardioprotection.
Characteristics of catechin- and theaflavin-mediated cardioprotection.
Exp Biol Med (Maywood). 2008 Apr ;233(4):427-33.

PubMed
Green tea reduces LDL oxidability and improves vascular function.
Green tea reduces LDL oxidability and improves vascular function.
J Am Coll Nutr. 2008 Apr ;27(2):209-13.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Review Pharmacology of Curcuma longa. [Planta Med. 1991]

Ammon HP, Wahl MA

Planta Med. 1991 Feb; 57(1):1-7.

Review Anticancer potential of curcumin: preclinical and clinical studies. [Anticancer Res. 2003]

Aggarwal BB, Kumar A, Bharti AC

Anticancer Res. 2003 Jan-Feb; 23(1A):363-98.
Review Curcumin: the story so far. [Eur J Cancer. 2005]

Sharma RA, Gescher AJ, Steward WP

Eur J Cancer. 2005 Sep; 41(13):1955-68.
How curcumin works preferentially with water soluble antioxidants. [J Am Chem Soc. 2001]

Jovanovic SV, Boone CW, Steenken S, Trinoga M, Kaskey RB

J Am Chem Soc. 2001 Apr 4; 123(13):3064-8.
Stability of curcumin in buffer solutions and characterization of its degradation products. [J Pharm Biomed Anal. 1997]

Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK

J Pharm Biomed Anal. 1997 Aug; 15(12):1867-76.
Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. [Carcinogenesis. 1995]

Huang MT, Ma W, Lu YP, Chang RL, Fisher C, Manchand PS, Newmark HL, Conney AH

Carcinogenesis. 1995 Oct; 16(10):2493-7.

A study on the fate of curcumin in the rat. [Acta Pharmacol Toxicol (Copenh). 1978]

Wahlström B, Blennow G

Acta Pharmacol Toxicol (Copenh). 1978 Aug; 43(2):86-92.
Absorption and tissue distribution of curcumin in rats. [Toxicology. 1980]

Ravindranath V, Chandrasekhara N

Toxicology. 1980; 16(3):259-65.
In vitro studies on the intestinal absorption of curcumin in rats. [Toxicology. 1981]

Ravindranath V, Chandrasekhara N

Toxicology. 1981; 20(2-3):251-7.
The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. [Xenobiotica. 1978]

Holder GM, Plummer JL, Ryan AJ

Xenobiotica. 1978 Dec; 8(12):761-8.
Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. [Planta Med. 1998]

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS

Planta Med. 1998 May; 64(4):353-6.

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. [Anticancer Res. 2001]

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY

Anticancer Res. 2001 Jul-Aug; 21(4B):2895-900.
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. [Clin Cancer Res. 2001]

Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP

Clin Cancer Res. 2001 Jul; 7(7):1894-900.
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. [Clin Cancer Res. 2004]

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP

Clin Cancer Res. 2004 Oct 15; 10(20):6847-54.

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. [Clin Cancer Res. 2004]

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP

Clin Cancer Res. 2004 Oct 15; 10(20):6847-54.

Curcumin: getting back to the roots. [Ann N Y Acad Sci. 2005]

Shishodia S, Sethi G, Aggarwal BB

Ann N Y Acad Sci. 2005 Nov; 1056():206-17.
Review Anticancer potential of curcumin: preclinical and clinical studies. [Anticancer Res. 2003]

Aggarwal BB, Kumar A, Bharti AC

Anticancer Res. 2003 Jan-Feb; 23(1A):363-98.
Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. [Cancer Res. 1994]

Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH

Cancer Res. 1994 Nov 15; 54(22):5841-7.
Review Epidemiology of digestive tract cancers in India. V. Large and small bowel. [Indian J Gastroenterol. 1999]

Mohandas KM, Desai DC

Indian J Gastroenterol. 1999 Jul-Sep; 18(3):118-21.

Enhancement of wound healing by curcumin in animals. [Wound Repair Regen. 1998]

Sidhu GS, Singh AK, Thaloor D, Banaudha KK, Patnaik GK, Srimal RC, Maheshwari RK

Wound Repair Regen. 1998 Mar-Apr; 6(2):167-77.
Review Angiogenesis. [J Biol Chem. 1992]

Folkman J, Shing Y

J Biol Chem. 1992 Jun 5; 267(16):10931-4.
Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. [Cell Growth Differ. 1998]

Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, Maheshwari RK

Cell Growth Differ. 1998 Apr; 9(4):305-12.
Curcumin is an in vivo inhibitor of angiogenesis. [Mol Med. 1998]

Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, Byers HR

Mol Med. 1998 Jun; 4(6):376-83.
Differential regulation of cytokines and transcription factors in liver by curcumin following hemorrhage/resuscitation. [Shock. 2003]

Gaddipati JP, Sundar SV, Calemine J, Seth P, Sidhu GS, Maheshwari RK

Shock. 2003 Feb; 19(2):150-6.

Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). [Indian J Med Res. 1980]

Deodhar SD, Sethi R, Srimal RC

Indian J Med Res. 1980 Apr; 71():632-4.
Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. [J Pharm Pharmacol. 1973]

Srimal RC, Dhawan BN

J Pharm Pharmacol. 1973 Jun; 25(6):447-52.
The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. [Crit Care Med. 2006]

Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P

Crit Care Med. 2006 Jul; 34(7):1874-82.

Review The peroxisome proliferator-activated receptors: ligands and activators. [Ann N Y Acad Sci. 1996]

Forman BM, Chen J, Evans RM

Ann N Y Acad Sci. 1996 Dec 27; 804():266-75.
The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. [Crit Care Med. 2006]

Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P

Crit Care Med. 2006 Jul; 34(7):1874-82.

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. [Nature. 1998]

Jiang C, Ting AT, Seed B

Nature. 1998 Jan 1; 391(6662):82-6.
Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. [J Cell Biochem. 2003]

Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE

J Cell Biochem. 2003 Nov 1; 90(4):732-44.
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. [Cancer Res. 2007]

Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB

Cancer Res. 2007 Apr 15; 67(8):3853-61.

Review "Spicing up" of the immune system by curcumin. [J Clin Immunol. 2007]

Jagetia GC, Aggarwal BB

J Clin Immunol. 2007 Jan; 27(1):19-35.
Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway. [Crit Care Med. 2005]

Hu M, Du Q, Vancurova I, Lin X, Miller EJ, Simms HH, Wang P

Crit Care Med. 2005 Nov; 33(11):2571-8.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. [Crit Care Med. 2001]

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR

Crit Care Med. 2001 Jul; 29(7):1303-10.
Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. [Crit Care Med. 2004]

Taneja R, Parodo J, Jia SH, Kapus A, Rotstein OD, Marshall JC

Crit Care Med. 2004 Jul; 32(7):1460-9.

Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. [Crit Care Med. 2004]

Collin M, Patel NS, Dugo L, Thiemermann C

Crit Care Med. 2004 Mar; 32(3):826-31.
The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. [Shock. 2004]

Abdelrahman M, Collin M, Thiemermann C

Shock. 2004 Dec; 22(6):555-61.

You are here: NCBI > Literature > PubMed Central (PMC)

Write to the Help Desk

PMC

Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation

Abstract

Articles from PPAR Research are provided here courtesy of Hindawi Publishing Corporation

Formats:

Related citations in PubMed

Cited by other articles in PMC

Links

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information